Shanghai – November 03, 2026 -- IASO Bio's FUCASO, the first BCMA-targeted CAR-T therapy approved in Singapore, will be covered under the country's Cancer Drug List (CDL) from December 1, 2026. The coverage follows the product's commercial launch in Singapore on November 3 with local partner Pills and Pokes.

Shanghai – September 25, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.